Excess transforming growth factor-β1 (TGF-β1) in the kidney leads to increased cell proliferation and deposition of extracellular matrix, resulting in progressive kidney fibrosis. TGF-β1, however, stabilizes and attenuates tissue injury through the activation of cytoprotective proteins, including heme oxygenase-1 (HO-1). HO-1 catabolizes pro-oxidant heme into substances with anti-oxidant, anti-apoptotic, anti-fibrogenic, vasodilatory and immune modulatory properties. Little is known regarding the molecular regulation of human HO-1 induction by TGF-β1 except that it is dependent on de novo RNA synthesis and requires a group of structurally related proteins called Smads. It is not known if other DNA binding proteins are required to initiate transcription of HO-1 and, furthermore, the promoter region(s) involved in TGF-β1-mediated induction of HO-1 has not been identified. The purpose of this study was to further delineate the molecular regulation of HO-1 by TGF-β1 in human renal proximal tubular cells.
INTRODUCTION

6
RNA was hybridized to a hybond membrane containing 3.5µg of human HO-1 and GAPDH cDNAs in the form of linearized plasmids (HO-1/pcDNA3.1 and GAPDH/pCR2.1TOPO, respectively).
Plasmid Constructs -The construction of the 4.5kb, 9.1kb and 11.6kb promoter fragments in a luciferase vector (pHOGL3/4.5, pHOGL3/9.1, pHOGL3/11.6) have been described previously (19, 21) . Additional HO-1 promoter deletion constructs (pHOGL3/9.7, pHOGL3/9.4, pHOGL3/8.5) were prepared by excising the 11.6kb promoter fragment from pHOGL3/11.6, with Sac2 and MluI followed by exonuclease digestion with 3 units of Bal-31. The ends were repaired with Klenow and then digested with NheI, leaving the 5' end of the promoter fragments blunt ended and the 3' end with an NheI overhang. The pHOGL3/11.6 vector was linearized, by digestion with Mlu I, filling in the overhang with Klenow, followed by digestion with NheI. This resulted in the pGL3 vector with 3.5kb of the HO-1 promoter with an NheI overhang and the other end of the vector containing a blunt end. The linear vector containing the 3.5kb HO-1 promoter was treated with calf intestinal alkaline phosphatase and then ligated with the Bal-31 digested inserts. The ligation products were transformed in DH10B competent cells and purified by Qiagen DNA isolation kits. All constructs were verified for orientation by sequencing and restriction digestion analysis.
Expression constructs for Smad2, Smad3, Smad4 and Smad7 were generously provided by Takeshi Imamura and Kohei Miyazono and have been described previously (22) . The Sp1 expression vector was kindly provided by Kun-Sang Chang (MDACC South Campus) and has been described elsewhere (52). promoter-reporter plasmids were co-transfected with equimolar amounts of Smad2, Smad3, Smad4, Smad7 or Sp1 expression vectors and pcDNA3 empty vector. Three-to-six hours post-transfection of promoter-reporter plasmids, cells were passaged into 6-well or 12-well tissue culture dishes to generate several sets of cells from the same transfection batch (a batch transfection protocol as previously described (19)). Transfected cells were allowed to recuperate for 24h prior to stimulus treatments with vehicle (BSA/HCl) or TGF-β1 (5-10ng/ml) for 16h. Luciferase activity was monitored using the luciferase reporter assay system (Promega) according to the manufacturer's instructions using a Sirius Luminometer (Berthold Detection Systems, Pforzheim, Germany).
Transfection and Measurement of Luciferase Activity
For Sp1 RNA interference, cells were transfected with a mixture of 4 different sequences designed to target Sp1 (siGENOME SMARTpool, 400nM) or a non-targeting oligonucleotide as a control for non-sequence-specific effects (mock: AAUGGAAGACCACUCCCACUC, 400nM), using Oligofectamine reagent. Oligofectamine without oligonucleotides was used as control. Cells were allowed to recover overnight before transfection with the promoter-reporter plasmids, treatment and luciferase activity measurements as described above. Some cells were analyzed for Sp1 protein, HO-1 protein or HO-1 RNA, by immunoblot or northern analysis, as described above.
Nuclear Extract and Electrophoretic Mobility Shift Assays (EMSA) Protocol -Nuclear Extracts were
prepared from HK-2 cells treated with TGF-β1 for 30 min. Cells were harvested in 50 ml conical tubes, pelleted, and resuspended in 300 ul of a hypotonic buffer containing10mM Hepes pH 7.9,.75mM spermidine, .75mM spermine, 0.1mM EDTA, 0.1mM EGTA, 1mM DTT, 10mM KCl and incubated on ice for 15 minutes. 15ul of 10% NP-40 was added and cells were vortexed for 10 seconds. The tube was centrifuged at 2000 rpm, 4 degrees for 15 seconds to pellet the nuclei. The supernatant was removed and the nuclear pellet was resuspended in 118.6ul of a nuclear resuspension buffer containing 20mM Hepes pH 7.9, 0.75mM spermidine, 0.75mM spermine, 0.2mM EDTA, 0.2mM EGTA, 25% glycerol, 2mM DTT. 21.4 ul of 4M KCl was added to the tube and was rocked vigorously on ice for 20 minutes. 46 ul of 8 cold resuspension buffer was added to the tube and mixed thoroughly. The nuclear extract was centrifuged at 10,000 rpm, 4 degrees for 15 minutes and the supernatant was transferred to a new tube and stored at -80 degrees.
The Sp1 and mutated Sp1 probes consisted of the oligonucleotides described in Fig. 7a annealed to their respective complements. Nuclear extracts (4ug) were incubated with oligonucleotide inhibitor (20 fold molar excess) or Sp1 antibody (1ug) in a 20 ul reaction containing 20% glycerol, 5mM MgCl2, 2.5mM EDTA, 2.5mM DTT, 250mM NaCl, 50mM Tris (pH7.5) and 500ug poly (dI.dC) for 20 minutes at room temperature with 0.1 pmol of an end labeled probe. The resulting protein-DNA complexes were analyzed by electrophoresis in a 5% (w/v) non-denaturing gel. The gels were fixed in methanol (10%) / acetic acid solution (10%), then dried and exposed to film.
Decoy Oligonucleotide Assays -The sequences of the forward strand for the wild-type, SBE-mutated and Sp1-mutated decoy oligonucleotides are presented in Fig 8A . Double stranded oligonucleotides were prepared by combining equal amounts of forward and reverse strand oligonucleotides in annealing buffer (10mM Tris (pH 8), 1mM EDTA, and 50mM NaCl), boiling for 10sec and slow cooling overnight at room temperature. The double stranded oligonucleotides were co-transfected in HK-2 cell cultures together with the pHOGL3/9.4 reporter construct, using 5 to 200 fold (3.25-130pmoles) greater molar equivalents of the double stranded decoy oligonucleotides versus the reporter construct, treated with TGF-β1 and assayed for luciferase activity as described above. Transcriptional activation of HO-1 by TGF-β1: The importance of de novo transcription was assessed by nuclear run-on analysis following stimulation with TGF-β1. HK-2 cells were treated with media containing vehicle (control) or TGF-β1 (10ng/ml) and nuclei were collected after 2h. Nuclei were then allowed to transcribe RNA in the presence of radiolabeled 32 P-UTP as described in the methods. As shown in Fig. 2A , TGF-β1 augmented HO-1 gene transcription by ~2 fold as compared to control cells.
Therefore, the induction of HO-1 by TGF-β1 occurs by direct increases in de novo transcription.
Since nitric oxide-mediated HO-1 induction occurs, at least in part, through increased HO-1 mRNA stability (6), the effects of TGF-β1 on HO-1 mRNA abundance and stability were explored by measuring the half-life of HO-1 mRNA in HK-2 cells. As shown in Fig. 2B , the half-life of HO-1 mRNA following TGF-β1 stimulation was ~2h and was similar in the presence or absence of additional TGF-β1
exposure. Similar results were obtained in the primary renal proximal tubular cell culture (data not shown). These data suggest that, similar to most other inducers of HO-1 including hemin, mRNA stability is not involved in TGF-β1-mediated HO-1 mRNA induction. HK-2 cells using equimolar amounts of 4.5, 8.5, 9.1, 9.4, 9.7 and 11.6kb promoter fragments of the HO-1 gene cloned into a promoterless luciferase vector (pGL3). Previously, we have shown that the 4.5kb
construct demonstrates significant promoter activity with heme, cadmium, and triterpenoids but not with TGF-β1 or oxidized LDL, implying that the mechansim of the upregulation of HO-1 differs depending on the inducer (3, 19, 20, 30). As shown in Figure 3A , the 4.5 and the 8.5kb promoter fragments were not responsive to TGF-β1 (5ng/ml, 16h). The 9.1kb fragment demonstrated increased luciferase activity (~1.5
fold) and the 9.4, 9.7 and 11.6kb fragments each demonstrated increased activity (~2 fold) following TGF-β1 exposure (Fig. 3A) . Therefore, two regions, a partial one between 8.5 and 9.1kb and a 280bp region between -9.1 and -9.4kb of the human HO-1 promoter are required for induction of HO-1 by TGF-β1. Computer analysis reveals that there is a putative SBE and several putative Sp1 binding sites within the region between -9.1 and -9.4kb (Fig. 3B ).
TGF-β1-mediated HO-1 induction is Smad-dependent:
In order to examine the effects of overexpression of Smads on TGF-β1 mediated reporter activity, HK-2 cells were transiently transfected with a TGF-β1-responsive HO-1 promoter in PGL3 (pHOGL3/11.6 or pHOGL3/9.4) and Smad7 (inhibitory Smad), Smad2, Smad3, Smad4 overexpression vectors or equimolar amounts of pcDNA3 empty vector. Cells were exposed to TGF-β1 (5ng/ml) for 16h, and luciferase activity was measured. Co-transfection of the inhibitory Smad7 with the HO-1 promoter blocked TGF-β1 inducible promoter activity ( whereas siRNA-based inhibition of Sp1 reduced basal reporter activity by ~28% compared to mock siRNA control and prevented TGF-β1-mediated activation (Fig. 6B ). As shown in 6C, siRNA against Sp1 reduced Sp1 proteins levels by ~76% which was sufficient to reduce reporter activity, but not TGF-β1-mediated increases in endogenous HO-1 mRNA or endogenous HO-protein (data not shown). 
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EMSA indicates that Sp1 interacts with the HO-1 promoter in vitro:
Effect of decoy oligonucleotides on TGF-β1-mediated HO-1 induction:
The region between 9.1 and 9.4kb of the HO-1 promoter is very GC rich, including a sequence of 22 G's and/or C's between the GTbox/GC-boxes 3' of the SBE. Attempts to make mutations in the pHOGL3/9.4 based on PCR were limited by several factors such as the size of the plasmid, difficulty in designing unique primers, and most notable, the string of G's and C's. In fact, in several experiments all elongation ceases at the GC box located at 9.19kb. Thus, we performed studies using a decoy oligonucleotide method that has been well cells were treated with TGF-β1 (5ng/ml) for 2-24h and TGF-β1 (3.0-7.0ng/ml) for 4h. RNA was collected and northern analysis was performed using 32 P-labeled human HO-1 and GAPDH cDNA probes as described in Experimental Procedures. B, HK-2 cells were treated with TGF (5 or 10ng/ml) for 2 -24h.
For immunoblot analysis, total cell lysates were collected and separated as described in Experimental
Procedures. Membranes were incubated with anti-HO-1 (1:5000) followed by a 1:10,000 dilution of peroxidase-conjugated goat anti-rabbit IgG antibody (1:10,000). Vehicle (V) for TGF-β1 (BSA/HCl) was used as control. Representative northern and immunoblots of n=3. 
